Vmbook Online ordering

Biotechnology

Tesaro Inc. was a biopharmaceutical company focused on the development and commercialization of therapies for cancer patients. The company was founded in 2010 and based in Waltham, Massachusetts.

In terms of financial performance, Tesaro's revenue has fluctuated over the years, but the company had been consistently reporting losses. For the year ended December 31, 2017, Tesaro reported revenue of $351.4 million, up from $162.2 million in 2016. However, the company's net loss for 2017 was $374.9 million, compared to a net loss of $248.2 million in 2016.

Tesaro's stock price (TSRO) experienced significant volatility in the past few years. In October 2017, Tesaro's stock reached its all-time high of around $180 per share, following positive clinical trial data for its ovarian cancer drug, Zejula. However, the stock price subsequently declined, a trend that was exacerbated by the company's steep net losses and increasing competition in the ovarian cancer market.

Unfortunately, on January 3, 2019, it was announced that GlaxoSmithKline (GSK) reached an agreement to acquire Tesaro for approximately $5.1 billion. As a result of the acquisition, Tesaro ceased to exist as a separate, publicly traded entity, and its stock was delisted from the NASDAQ stock exchange.

In summary, Tesaro was a biopharmaceutical company focused on oncology therapies, with fluctuations in revenue and significant financial losses leading up to its acquisition by GSK.